Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 10/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.35 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.35 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.34 |
| ▸ | MELK | Q14680 | 4/20 | 0.33 |
| ▸ | JAK1 | P23458 | 2/20 | 0.33 |
| ▸ | JAK3 | P52333 | 2/20 | 0.33 |
| ▸ | LTA4H | P09960 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30586614 | 1.00 | JAK2 (0.36) | JAK2PIK3CAPIK3CBMCHR1PDE1B | |
| SCHEMBL24175713 | 0.93 | JAK2 (0.37) | JAK2PIK3CAPIK3CBMCHR1PDE1B | |
| SCHEMBL30586617 | 0.91 | MCHR1 (0.35) | JAK2PIK3CAPIK3CBMCHR1PDE1B | |
| SCHEMBL26326391 | 0.90 | JAK2 (0.35) | JAK2PIK3CAPIK3CBMCHR1PDE1B | |
| SCHEMBL30586615 | 0.90 | JAK2 (0.35) | JAK2PIK3CAPIK3CBMCHR1PDE1B | |
| SCHEMBL24175716 | 0.83 | JAK2 (0.32) | JAK2MCHR1PDE1B | |
| SCHEMBL24175780 | 0.83 | JAK2 (0.36) | JAK2PIK3CAPIK3CBMCHR1PDE1B | |
| SCHEMBL24175715 | 0.77 | JAK2 (0.33) | JAK2MCHR1PDE1BJAK1JAK3 | |
| SCHEMBL24165274 | 0.71 | JAK2 (0.39) | JAK2MCHR1JAK1JAK3LTA4H | |
| SCHEMBL1356795 | 0.69 | PDE1B (0.36) | PDE1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11767323-B2 | Tricyclic pyridone compounds as JAK2 V617F inhibitors | INCYTE CORPORATION (US) | 2023-09-26 | — | — | US | disclosed |
| US-11767323-B2 | Tricyclic pyridone compounds as JAK2 V617F inhibitors | INCYTE CORPORATION (US) | 2023-09-26 | — | — | US | disclosed |
| US-20220002299-A1 | TRICYCLIC PYRIDONE COMPOUNDS AS JAK2 V617F INHIBITORS | INCYTE CORPORATION | 2022-01-06 | — | — | US | disclosed |
| WO-2022006456-A1 | TRICYCLIC PYRIDONE COMPOUNDS AS JAK2 V617F INHIBITORS | INCYTE CORPORATION (US) | 2022-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220002299-A1 | TRICYCLIC PYRIDONE COMPOUNDS AS JAK2 V617F INHIBITORS | JAK2, JAK1, JAK3 | JAK2 1/4885PIK3CA 54/4885PIK3CB 85/4885 |
| US-11767323-B2 | Tricyclic pyridone compounds as JAK2 V617F inhibitors | JAK2, JAK1, JAK3 | JAK2 1/4885PIK3CA 54/4885PIK3CB 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.